Search Results - "Walko, C"

Aprepitant: drug–drug interactions in perspective by Aapro, M.S., Walko, C.M.

“…The implications of chemotherapeutic drug–drug interactions can be serious and thus need to be addressed. This review concerns the potential interactions of…”
Get full text

Oral single-agent chemotherapy in older patients with solid tumours: A position paper from the International Society of Geriatric Oncology (SIOG) by Biganzoli, L, Lichtman, S, Michel, J.-P, Papamichael, D, Quoix, E, Walko, C, Aapro, M

“…Highlights • Oral chemotherapy may be well suited to older patients with solid tumours. • Implications for adherence must be considered. • Oral capecitabine or…”
Get full text

Synthesis, Magnetic Properties, and Electronic Structure of Magnetic Topological Insulator MnBi2Se4 by Zhu, Tiancong, Bishop, Alexander J, Zhou, Tong, Zhu, Menglin, O’Hara, Dante J, Baker, Alexander A, Cheng, Shuyu, Walko, Robert C, Repicky, Jacob J, Liu, Tao, Gupta, Jay A, Jozwiak, Chris M, Rotenberg, Eli, Hwang, Jinwoo, Žutić, Igor, Kawakami, Roland K

“…The intrinsic magnetic topological insulators MnBi2Te4 and MnBi2Se4 support novel topological states related to symmetry breaking by magnetic order. Unlike…”
Get full text

Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer by Brewer, N T, Defrank, J T, Chiu, W K, Ibrahim, J G, Walko, C M, Rubin, P, Olajide, O A, Moore, S G, Raab, R E, Carrizosa, D R, Corso, S W, Schwartz, G, Peppercorn, J M, McLeod, H L, Carey, L A, Irvin, Jr, W J

“…CYP2D6 is a critical enzyme in the metabolism of tamoxifen and potentially a key determinant in breast cancer outcomes. Our study examined patients' beliefs…”
Get more information

Ovarian cancer and aging: Hints from the tissue environment? by Extermann, M., Walko, C., Mishra, A., Cao, B., Chon, H., Cristea, M., Berglund, A., Chern, J.Y., Cubitt, C., Gomes, A.P., Hoffman, M., Kim, J., Marchion, D., Sansil, S., Sehovic, M., Shahzad, M., Welsh, E., Zhang, Y.

Get full text

SIOG2022-0160 - Ovarian cancer and aging: Hints from the tissue environment? by Extermann, M., Walko, C., Mishra, A., Cao, B., Chon, H., Cristea, M., Berglund, A., Chern, J.Y., Cubitt, C., Gomes, A.P., Hoffman, M., Kim, J., Marchion, D., Sansil, S., Sehovic, M., Shahzad, M., Welsh, E., Zhang, Y.

Get full text

Beneficial Effect of High-Dose Iv Busulfan (Bu) Delivered by Prolonged Continuous Infusion (CI) on Relapse Rate and Overall Survival (OS) in Matched Related and Unrelated Allogeneic Transplant Patients with Hematologic Malignancies by Walko, C, Ivanova, A, Whitley, J, Rao, K, Gabriel, D, Serody, J, Comeau, T, Coghill, J, Armistead, P, Sarantopoulos, S, Wood, W, Shea, T

Get full text

Functional characterization of variants of unknown significance (VUS) in patients and their responsiveness to targeted therapy drugs (TTD) by Tarcic, G., Walko, C.M., McLeod, H.L., Hicks, J.K., Barbash, Z., Edelheit, O., Miron, B., Vidne, M., Padron, E.

Get full text

Worsening of ovarian cancer prognosis with age: an exploration of pharmacokinetics, body composition, and biology by Extermann, M., Walko, C., Mishra, A., Thomas, K., Cao, B., Chon, H.S., Critea, M., Berglund, A., Chem, J.Y., Cubitt, C., Gomes, A.P., Hoffman, M., Kim, J., Marchion, D., Petersson, F., Sansil, S., Sehovic, M., Shahzad, M., Welsh, E., Zhang, Y.

Get full text

SIOG2021-0170 - Worsening of ovarian cancer prognosis with age: an exploration of pharmacokinetics, body composition, and biology by Extermann, M., Walko, C., Mishra, A., Thomas, K., Cao, B., Chon, H.S., Critea, M., Berglund, A., Chem, J.Y., Cubitt, C., Gomes, A.P., Hoffman, M., Kim, J., Marchion, D., Petersson, F., Sansil, S., Sehovic, M., Shahzad, M., Welsh, E., Zhang, Y.

Get full text

Scanning tunneling microscopy study of the antiferromagnetic topological insulator MnBi2Se4 by Walko, Robert C., Zhu, Tiancong, Bishop, Alexander J., Kawakami, Roland K., Gupta, Jay A.

Get full text

273: Safety and efficacy of high-dose busulfan by 90-hour continuous infusion in hematologic malignancy patients undergoing allogeneic stem cell transplants by Shea, T, Walko, C, Serody, J, Gabriel, D, Comeau, T, Rao, K, Ivanova, A, Sharf, A, Krasnov, C, Coghill, A, Whitley, J, Lindley, C

Get full text

Capecitabine: A review by Walko, Christine M., Lindley, Celeste

“…Fluorouracil (FU) is an antimetabolite with activity against numerous types of neoplasms, including those of the breast, esophagus, larynx, and…”
Get full text

Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors by Coulter, Don W, Walko, Christine, Patel, Jai, Moats-Staats, Billie M, McFadden, Andrew, Smith, Scott V, Khan, Wasiuddin A, Bridges, Arlene S, Deal, Allison M, Oesterheld, Javier, Davis, Ian J, Blatt, Julie

“…A pediatric study has established a maximum tolerated dose (MTD) for temsirolimus (Tem) of more than 150 mg/m intravenously/week. A phase I trial was conducted…”
Get full text

Scanning tunneling microscopy study of the antiferromagnetic topological insulator MnBi2Se4 by Walko, Robert C., Zhu, Tiancong, Bishop, Alexander J., Kawakami, Roland K., Gupta, Jay A.

“…Topological insulators with intrinsic magnetic ordering such as MnBi2Se4 have been predicted to host many exotic topological phenomena including…”
Get full text

Effect of race on cyclophosphamide (CP) metabolism by Walsh, M. D., Combest, A. J., Hull III, J. H., Dvorak, A., Hoskins, J. M., Dees, E. C., McLeod, H. L., Walko, C. M.

“…Abstract only…”
Get full text

Pharmacoepidemiology of clinically relevant hypothyroidism and hypertension from sunitinib and sorafenib by Walko, C. M., Aubert, R. E., La-Beck, N. M., Hawk, G., Herrera, V., Kourlas, H., Epstein, R. S., McLeod, H. L.

“…Abstract only…”
Get full text

Effect of aprepitant (AP) on cyclophosphamide (CPA) pharmacokinetics (PK) in early breast cancer patients by Walko, C. M., Yu, Y. A., Bhushan, S., Spasojevic, I., Carey, L., Collichio, F., Armstrong, D., Dees, E. C.

“…Abstract only 588 Background: AP, a moderate inhibitor of CYP3A4, is a selective neurokinin 1 receptor antagonist recommended by the ASCO guidelines for…”
Get full text

Response to degarelix after resistance to luteinizing hormone–releasing hormone agonist therapy for metastatic prostate cancer by Raddin, Ryan S, Walko, Christine M, Whang, Young E

“…Androgen deprivation with a luteinizing hormone–releasing hormone (LH–RH) agonist is the standard treatment for patients with metastatic prostate cancer who…”
Get full text

Low Overexpression of HER-2/PPPNeu in Advanced Colorectal Cancer Limits the Usefulness of Trastuzumab (Herceptin registered ) and Irinotecan as Therapy. A Phase II Trial by Ramanathan, R K, Hwang, J J, Zamboni, W C, Sinicrope, F A, Safran, H, Wong, M K, Earle, M, Brufsky, A, Evans, T, Troetschel, M, Walko, C, Day, R, Chen, H X, Finkelstein, S

“…To determine the response rate of trastuzumab and irinotecan in HER-2/neu overexpressing advanced colorectal cancer (CRC), determine the frequency of HER-2/neu…”
Get full text